Evidence map›Paper›PMID 40757104›Full record

ArticleJournal of medicine and life2025

B-cell acute lymphoblastic leukemia and lymphoblastic lymphoma with p190

Budiono Raharjo, Catherine Keiko Gunawan, Stephani Linggawan, Siprianus Ugroseno Yudho Bintoro, Anton Sumarpo

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Budiono RaharjoFaculty of Medicine, Universitas Wijaya Kusuma Surabaya, Surabaya, Indonesia.
Catherine Keiko GunawanFaculty of Medicine, Maranatha Christian University, Bandung, Indonesia.
Stephani LinggawanFaculty of Medicine, Universitas Wijaya Kusuma Surabaya, Surabaya, Indonesia.
Siprianus Ugroseno Yudho BintoroDepartment of Internal Medicine, Faculty of Medicine, Universitas Airlangga -Dr. Soetomo General Hospital, Surabaya, Indonesia.
Anton SumarpoDepartment of Clinical Pathology, Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphoblastic lymphoma (LBL) is a rare and aggressive lymphoblastic neoplasm, accounting for approximately 2% of non-Hodgkin lymphoma cases. Despite sharing clinical and morphological similarities with acute lymphoblastic leukemia (ALL), LBL is characterized by distinct genetic abnormalities. Due to the ambiguity surrounding treatments, the prognosis for LBL remains poor, with complete remission rates between 40-58% and 5-year disease-free survival rates between 36-70%. We present a case of a 42-year-old man diagnosed with B-acute lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (LBL). The diagnosis was challenging due to the rarity of the condition and the overlapping features of LBL and ALL. This case report highlights the predominance of lymphoblasts and the presence of the p190 (e1a2)

Indexed as

Fusion Proteins, bcr-ablPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-bcrAdultHumansMaleFusion Proteins, bcr-ablProto-Oncogene Proteins c-bcracute lymphoblastic leukemiaB-cell lymphoblastic lymphomaBCR::ABL1

Identifiers

PMID40757104
PMCPMC12314840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.